Nonaddictive hydromorphone hydrogel for muscle and joint pain
Nonaddictive opioid prodrug nanomedicine for musculoskeletal pain
A long-lasting, non-addictive gel medicine that releases pain relief right at sore muscles and joints without reaching the brain.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-11136478 on NIH RePORTER |
What this research studies
You would receive a temperature-sensitive gel placed near a painful joint or muscle that slowly releases a modified form of the opioid hydromorphone where it is needed. The medicine is attached to a large carrier so it stays at the site and is taken up by local cells, releasing pain relief over many days while limiting drug exposure to the spinal cord and brain. In animal models of osteoarthritis the gel provided strong pain relief for more than two weeks without signs of central opioid effects. The team aims to make pain control that is potent yet avoids the addiction and systemic side effects of traditional opioids.
Who could benefit from this research
Good fit: People with localized musculoskeletal pain such as osteoarthritis or joint/muscle pain who need stronger, targeted relief and want to avoid systemic opioids would be the ideal candidates.
Not a fit: Patients with widespread or centrally mediated pain conditions, those needing whole-body opioid effects, or anyone with allergies to the components likely would not benefit from this local gel approach.
Why it matters
Potential benefit: If successful, this approach could give longer-lasting local pain relief for musculoskeletal conditions while reducing the risk of addiction and systemic side effects.
How similar studies have performed: Related local opioid-delivery ideas have shown promising results in animal models, but similar approaches remain largely preclinical and human data are limited.
Where this research is happening
Omaha, United States
- University of Nebraska Medical Center — Omaha, United States (Active)
Researchers
- Principal investigator: Wang, Dong — University of Nebraska Medical Center
- Study coordinator: Wang, Dong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.